Ruth E. Joplin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ruth E. Joplin has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Luca Fabris
Department of Medicine (DIMED), University of Padova, Padua, Italy
2 shared publications Alastair J. Strain
1 shared publication- Carlo Spirli
Liver Center and Section of Digestive Diseases, Department of Internal Medicine, Yale University, New Haven, CT 06519, USA
1 shared publication - Deirdre A. Kelly
Birmingham Children’s Hospital
1 shared publication Giorgio Ballardini
1 shared publicationHeather A. Crosby
1 shared publication
Latest Publications
- Open Access
- 13 January 2017
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 18 (1) , 149
Autocrine and Paracrine Mechanisms Promoting Chemoresistance in Cholangiocarcinoma
Resistance to conventional chemotherapeutic agents, a typical feature of cholangiocarcinoma, prevents the efficacy of the therapeutic arsenal usually used to combat malignancy in humans. Mechanisms of chemoresistance by neoplastic cholangiocytes include evasion of drug-induced apoptosis mediated by autocrine and paracrine cues released in the tumor microenvironment. Here, recent evidence regarding molecular mechanisms of chemoresistance is reviewed, as well as associations between well-developed chemoresistance and activation of the cancer stem cell compartment. It is concluded that improved understanding of the complex interplay between apoptosis signaling and the promotion of cell survival represent potentially productive areas for active investigation, with the ultimate aim of encouraging future studies to unveil new, effective strategies able to overcome current limitations on treatment.
- 13 January 2017
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 18 (1) , 149
Open AccessAutocrine and Paracrine Mechanisms Promoting Chemoresistance in Cholangiocarcinoma
Resistance to conventional chemotherapeutic agents, a typical feature of cholangiocarcinoma, prevents the efficacy of the therapeutic arsenal usually used to combat malignancy in humans. Mechanisms of chemoresistance by neoplastic cholangiocytes include evasion of drug-induced apoptosis mediated by autocrine and paracrine cues released in the tumor microenvironment. Here, recent evidence regarding molecular mechanisms of chemoresistance is reviewed, as well as associations between well-developed chemoresistance and activation of the cancer stem cell compartment. It is concluded that improved understanding of the complex interplay between apoptosis signaling and the promotion of cell survival represent potentially productive areas for active investigation, with the ultimate aim of encouraging future studies to unveil new, effective strategies able to overcome current limitations on treatment.
- Open Access
- 31 December 2000
- Published by Elsevier in The American Journal of Pathology
- Vol. 157 (6) , 2161
Correction
- 31 December 2000
- Published by Elsevier in The American Journal of Pathology
- Vol. 157 (6) , 2161
Open AccessCorrection